Marker Therapeutics, Inc. declares proposed public providing of widespread shares
HOUSTON, March 11, 2021 / PRNewswire / – Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology firm specializing within the improvement of next-generation T-cell-based immunotherapies for the therapy of hematologic malignancies and stable tumors , right now introduced that it has launched a subscribed public providing of shares of its strange shares. As well as, Marker expects to grant the underwriters a 30 day choice to buy further shares of its widespread shares. All shares to be offered beneath the supply should be offered by Marker. The Provide is topic to market and different situations and there could be no assurance that the Provide might be profitable or not, or the precise dimension or phrases of the Provide.
Piper sandler & Co. acts as the one lively accounting supervisor for the providing.
The proposed supply is being made in accordance with a previous registration assertion, together with a base prospectus, filed by Marker which was declared efficient by the Securities and Trade Fee (“SEC”) on June 25, 2019. The providing might be made solely by the use of a written prospectus and a prospectus complement forming a part of the registration assertion. An digital copy of the preliminary prospectus complement and the associated prospectus referring to the providing might be out there on the SEC’s web site at www.sec.gov. Copies of the preliminary prospectus complement, when out there, and the associated prospectus referring to the providing could be obtained by contacting Piper sandler & Co., Attn: Prospectus Division, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by cellphone at (800) 747-3924 or by e-mail at [email protected] The ultimate phrases of the supply might be disclosed in a last prospectus complement which might be filed with the SEC.
This press launch doesn’t represent a proposal to promote or the solicitation of a proposal to purchase such securities, nor any sale of such securities in any state or different jurisdiction the place such a proposal, solicitation or sale could be illegal earlier than. registration or qualification beneath the securities legal guidelines of such state or different jurisdiction.
This press launch comprises forward-looking statements for the needs of the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. Statements on this press launch regarding the expectations, plans, enterprise prospects or future efficiency of the corporate, in addition to some other assertion relating to assumptions made or expectations relating to future occasions, situations, efficiency or different issues are “forward-looking statements”. Ahead-looking statements embrace statements relating to the timing, dimension and completion of the proposed public providing. Ahead-looking statements are, by their nature, topic to dangers, uncertainties and different elements that would trigger precise outcomes to vary materially from these set forth in such statements. These dangers, uncertainties and elements embrace, however will not be restricted to, the dangers set out within the Firm’s most up-to-date Annual Report on Kind 10-Okay and different paperwork filed with the SEC out there by way of EDGAR on the following handle : www.sec.gov. These dangers and uncertainties could also be magnified by the COVID-19 pandemic and its impression on our enterprise and the worldwide financial system. The Firm assumes no obligation to replace our forward-looking statements whether or not because of new info, future occasions or in any other case, after the date of this press launch.
Present unique content material to obtain multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301246042.html
SOURCE Marker Therapeutics, Inc.